CN101683387A - Medication and preparation method and application thereof - Google Patents

Medication and preparation method and application thereof Download PDF

Info

Publication number
CN101683387A
CN101683387A CN200810223440A CN200810223440A CN101683387A CN 101683387 A CN101683387 A CN 101683387A CN 200810223440 A CN200810223440 A CN 200810223440A CN 200810223440 A CN200810223440 A CN 200810223440A CN 101683387 A CN101683387 A CN 101683387A
Authority
CN
China
Prior art keywords
radix ginseng
extract
eluent
salviae miltiorrhizae
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN200810223440A
Other languages
Chinese (zh)
Other versions
CN101683387B (en
Inventor
罗国安
李连达
王义明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGZHOU XIANGXUE PHARMACEUTICAL CO Ltd
Original Assignee
GUANGZHOU XIANGXUE PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101683387(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GUANGZHOU XIANGXUE PHARMACEUTICAL CO Ltd filed Critical GUANGZHOU XIANGXUE PHARMACEUTICAL CO Ltd
Priority to CN2008102234408A priority Critical patent/CN101683387B/en
Publication of CN101683387A publication Critical patent/CN101683387A/en
Application granted granted Critical
Publication of CN101683387B publication Critical patent/CN101683387B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a medication and a preparation method and application thereof Active components of the medication are ginseng extract and salvia miltiorrhiza extract; a weight ratio between the ginseng extract and the salvia miltiorrhiza extract is 1:(0.1-20); a weight percentage content of total ginsenoside in the ginseng extract is larger than 50%; and a weight percentage contentof salvianolic acid in the salvia miltiorrhiza extract is larger than 50%. As shown in the result of Wistar rat myocardial infarction experiment and myocardial ischemia experiment, the reconstitutionof total ginsenoside and salvianolic acid has an optimal therapeutic effect, can effectively control Wistar rat myocardial infarction area and improve myocardial ischemia situation, furthermore, hasa same therapeutic effect with an original medicinal material reconstitution prescription. Pharmaceutical ingredient of the medication of the invention is clear and the quality of the medication can be controlled easily.

Description

A kind of medicine and preparation method thereof and application
Technical field
The present invention relates to a kind of medicine and preparation method thereof and application, particularly relating to a kind of is the medicine and preparation method thereof and application of raw material with Radix Ginseng and Radix Salviae Miltiorrhizae.
Background technology
Cardiovascular and cerebrovascular disease is a class disease of serious harm human health, and along with the increase of social pressure and the aggravation of China's aged tendency of population, cardiovascular disease is high at the sickness rate of China.Therefore, the medicine of exploitation treatment cardiovascular disease has great social significance.
The Chinese crude drug Radix Ginseng is the root of araliaceae ginseng plant's Radix Ginseng (Panax.ginsengC.A.Mey).The root sweet in the mouth of Radix Ginseng, little hardship, warm in nature have regulating QI nourish blood, the calm the nerves effect of Fructus Alpiniae Oxyphyllae, the cough-relieving of promoting the production of body fluid, nourishing and fit keeping function.Mainly contain saponin in the Radix Ginseng; volatile oil (Panaxynol; the Panacene; sterol; fatty acid); sugar; aminoacid; composition such as peptide and vitamins; up to the present; from Radix Ginseng Rubra; be divided in Radix Ginseng and the Radix Ginseng from obtaining 40 kinds of ginsenosides, i.e. ginsenoside R0; Ra1; Ra2; Ra3; Rb1; Rb2; Rb3; Rc; Rd; Re; Rf; 20-glc-Rf; Rg1; Rg2; 20 (R)-ginsenoside-Rg2; Rg3; 20 (S)-ginsenoside-Rg3; Rg5; Rh1; 20 (R)-ginsenoside-Rh1; Rh2; 20 (S)-ginsenoside-Rh2s; Rh4; Ri; Rs1; Rs2; the malonyl ginsenoside Rb1; Rb2; Rc; Rd; Radix Notoginseng ginsenoside R1; Radix Panacis Quinquefolii saponin R1; 20 (R)-ginsenoside-La; F4; 25-hydroxy-ginsenoside-Rg2; 25-hydroxy-ginsenoside-Rg2; Ia; Ib; koryoginsenoside-Rg1 and-Rg2.The stem of Radix Ginseng, leaf and flower also contain ginsenoside's constituents, also can replace Radix Ginseng to be used as medicine.In addition, the processing of root process, the process of preparing Chinese medicine with Radix Ginseng are prepared into Radix Ginseng, Radix Ginseng Rubra, also can be used as medicine.
The Chinese crude drug Radix Salviae Miltiorrhizae is the exsiccant root and rhizome of labiate Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Bunge.).Radix Salviae Miltiorrhizae has pharmacological action widely aspect cardiovascular disease, wherein salvianolic acid is the organic acid chemical compound that a class contains phenolic hydroxyl group, it is ingredient important in the red sage root water soluble ingredient, can alleviate hypoxic-ischemic blood vessel endothelium injury caused, promote the blood vessel endothelium hypertrophy, have the myocardial cell injury, atherosclerosis, anticoagulant and the antithrombotic effect that improve due to the hypoxic-ischemic.The effect that salviol acid A, B, C, D, E, F, G, H, I and different salvianolic acid C etc. have very strong anti peroxidation of lipid and remove free radical; wherein the activity of two composition salviol acid A (SalA) that content is the highest and salvianolic acid B (SalB) is the strongest, and the cell membrane damage that lipid peroxidation is caused has effects such as significant protection and atherosclerosis.When the oxygen-derived free radicals that produces in the organism metabolism process can not be eliminated, can produce harmful damage to body, wherein myocardial cell is injured particularly remarkable.Oxygen-derived free radicals has the active effect of obvious suppression potassium-channel, and SalA then has the effect that promotes that potassium-channel is open, and can reverse the activity of the potassium-channel that is suppressed by oxygen-derived free radicals, thereby plays a protective role.
At present, the method that the reuse n-butanol extraction is handled behind the general many employing ethanol extractions of the extracting method of saponin in the Radix Ginseng, the shortcoming of this method is that extracting operation is loaded down with trivial details, is easy to generate emulsion, makes troubles to operation.In addition, the boiling point of n-butyl alcohol higher (117.7 ℃) is difficult to volatilization and removes, thereby it is easy to residual in extract.The extracting method that adopts water extract-alcohol precipitation is also arranged, but technology is loaded down with trivial details, energy consumption is big.More the water-soluble phenolic acids component of Radix Salviae Miltiorrhizae adopts water extract-alcohol precipitation, water to carry the back and crosses that resin is crossed macroporous resin (Chinese patent CN1384090A) or polyamide column (Chinese patent CN1242364A) behind precipitate with ethanol (Chinese patent CN1129572A), the water extract-alcohol precipitation again, water is carried the back successively with polyamide column and macroporous resin chromatography (Chinese patent CN1459448A), and methods such as decompression or lyophilization obtain then.But there is following shortcoming in the method for above extraction Radix Salviae Miltiorrhizae total phenolic acids: 1, in the prepared Radix Salviae Miltiorrhizae extract, the content of Radix Salviae Miltiorrhizae total phenolic acids is not high, and productive rate is lower, generally 2～4%; 2, adopt the high concentration ethanol precipitate with ethanol, the industrialization production security is reduced greatly, the ethanol consumption is big, the production cost height; 3, high concentration ethanol precipitate with ethanol step influences the productive rate of Radix Salviae Miltiorrhizae total phenolic acids in the Radix Salviae Miltiorrhizae extract; 4, need a large amount of condensed water, be not easy to industrialized great production, operation is comparatively complicated; 5, generally choose danshensu and protocatechualdehyde index components, but the protocatechualdehyde toxic side effect represents the activity of Radix Salviae Miltiorrhizae very unreasonable with danshensu as control red sage formulation quality.
Summary of the invention
The purpose of this invention is to provide a kind of medicine and preparation method thereof and application, this curable substance and/or prevention angiopathy, the differentiation of promotion mesenchymal stem cells MSCs become cardiac-like muscle cell with the inducing bone mesenchymal differentiation of stem cells.
Described angiopathy can be cardiovascular disease, cerebrovascular disease or peripheral vascular disease; Described cardiovascular disease can be coronary heart disease, angina pectoris, myocardial ischemia or anoxia or myocardial infarction, and described cerebrovascular disease can be ischemic cerebrovascular or vascular dementia, and described peripheral vascular disease can be rhomboembolia type cerebral vasculitis or phlebothrombosis.
Medicine provided by the present invention, the raw material that its active component is made up of Radix Ginseng and Radix Salviae Miltiorrhizae is made; Described Radix Ginseng be root, stem, the leaf of plant Radix Ginseng and spend at least a; Described Radix Salviae Miltiorrhizae is the root of plant Radix Salviae Miltiorrhizae; The ratio of weight and number of described Radix Ginseng and Radix Salviae Miltiorrhizae is 1: (0.08-20).Wherein, Radix Ginseng and Radix Salviae Miltiorrhizae can also can be the bright medical material of Radix Ginseng and Radix Salviae Miltiorrhizae for concocting back Radix Ginseng and Radix Salviae Miltiorrhizae.
The active component of this medicine specifically can be Radix Ginseng extract and Radix Salviae Miltiorrhizae extract, and the ratio of weight and number of described Radix Ginseng extract and Radix Salviae Miltiorrhizae extract is 1: (0.1-20); In the described Radix Ginseng extract, the quality percentage composition of Radix Ginseng total saponins is greater than 50%, is preferably more than to equal 80%, as 80-83%; Wherein, Radix Ginseng total saponins comprises ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1 and ginsenoside Rf, the quality percentage composition of described ginsenoside Rg1 in Radix Ginseng total saponins is more than or equal to 2%, the quality percentage composition of ginsenoside Re in Radix Ginseng total saponins is more than or equal to 2.5%, and the quality percentage composition of ginsenoside Rb1 in Radix Ginseng total saponins is more than or equal to 2%; In the described Radix Salviae Miltiorrhizae extract, the quality percentage composition of salvianolic acid is greater than 50%, is preferably more than to equal 80%, as 89-95%.
Medicine of the present invention when needed, can add pharmaceutically acceptable carrier, makes tablet, granule, capsule, drop pill, oral cavity disintegration tablet, injection, infusion solution, slow-release tablet agent, slow controlled release micro pill, aerosol or inhalant; Described carrier comprises diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier or the lubricant etc. of pharmaceutical field routine, can also add flavouring agent or sweeting agent etc.
Radix Ginseng extract in the medicine of the present invention and Radix Salviae Miltiorrhizae extract can be prepared as follows:
1) with ethanol water or water Radix Ginseng is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain ginsenoside's extracting solution; With ethanol water or water Radix Salviae Miltiorrhizae is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain the salvianolic acid extracting solution;
2) adopting macroporous adsorptive resins to above-mentioned steps 1) ginsenoside's extracting solution of obtaining adsorbs, first water or ethanol water eluting water solubility impurity, and then with ethanol aqueous wash deresination post, the collection eluent obtains the Radix Ginseng total saponins eluent; Adopting macroporous adsorptive resins to above-mentioned steps 1) the salvianolic acid extracting solution that obtains adsorbs, and washes the dehydration solubility impurity earlier with water, and then with ethanol aqueous wash deresination post, the collection eluent obtains the salvianolic acid eluent;
3) to above-mentioned steps 2) the Radix Ginseng total saponins eluent that obtains carries out drying, obtains Radix Ginseng extract; To above-mentioned steps 2) the salvianolic acid eluent that obtains carries out drying, obtains Radix Salviae Miltiorrhizae extract.
When preparing ginsenoside's extracting solution above-mentioned steps 1), in the described ethanol water, alcoholic acid volumn concentration is 50-95%, is preferably 90%; The ratio of weight and number of described Radix Ginseng and ethanol water is 1: (6-15), be preferably 1: 10; Described return time is 30min-120min, is preferably 60min; When preparing the salvianolic acid extracting solution in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 10-60%, is preferably 50%; The ratio of weight and number of described Radix Salviae Miltiorrhizae and ethanol water is 1: (5-15), be preferably 1: 10; Described return time is 30min-120min, is preferably 30min;
When preparing ginsenoside's eluent described step 2), during the eluting water solubility impurity, alcoholic acid volumn concentration is less than 10% in the described ethanol water; During the eluting resin column, alcoholic acid volumn concentration is 50-90% in the described ethanol water, is preferably 60-70%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
When preparing the salvianolic acid eluent described step 2), during the eluting resin column, alcoholic acid volumn concentration is 30-90% in the described ethanol water, is preferably 40-60%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
In the described step 3), it is 50-60 ℃ that Radix Ginseng total saponins eluent and salvianolic acid eluent are carried out exsiccant temperature.
Radix Ginseng extract in the medicine of the present invention and Radix Salviae Miltiorrhizae extract can also be prepared as follows:
1) with Radix Ginseng and Radix Salviae Miltiorrhizae according to 1: ratio of weight and number (0.08-20) mixes, with ethanol water or water the mixture of Radix Ginseng and Radix Salviae Miltiorrhizae is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain containing the mixed extract of ginsenoside and salvianolic acid;
Described Radix Ginseng be root, stem, the leaf of plant Radix Ginseng and spend at least a;
Described Radix Salviae Miltiorrhizae is the root of plant Radix Salviae Miltiorrhizae;
2) adopting macroporous adsorptive resins to above-mentioned steps 1) mixed extract that obtains adsorbs, wash the dehydration solubility impurity earlier with water, and then, collect eluent with ethanol aqueous wash deresination post, obtain containing the mixing eluent of Radix Ginseng total saponins and salvianolic acid;
3) to above-mentioned steps 2) the mixing eluent that obtains carries out drying, obtains the mixed extract of Radix Ginseng extract and Radix Salviae Miltiorrhizae extract.
When preparing mixed extract in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 30-90%%, is preferably 60%; The ratio of weight and number of described Radix Ginseng and Radix Salviae Miltiorrhizae mixture and ethanol water is 1: (6-15), be preferably 1: 10; Described return time is 30-120min, is preferably 45min;
When preparation mixed eluent described step 2), during the eluting resin column, alcoholic acid volumn concentration was 30-90% in the described ethanol water, is preferably 50-70%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
In the described step 3), it is 50-60 ℃ that the mixing eluent is carried out exsiccant temperature.
Another object of the present invention provides manufacturing method for above mentioned medicine.
Medicine provided by the present invention can adopt any one method in following two kinds of methods to prepare.
Wherein a kind of preparation method may further comprise the steps:
1) with ethanol water or water Radix Ginseng is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain ginsenoside's extracting solution; With ethanol water or water Radix Salviae Miltiorrhizae is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain the salvianolic acid extracting solution;
2) adopting macroporous adsorptive resins to above-mentioned steps 1) ginsenoside's extracting solution of obtaining adsorbs, first water or ethanol water eluting water solubility impurity, and then with ethanol aqueous wash deresination post, the collection eluent obtains the Radix Ginseng total saponins eluent; Adopting macroporous adsorptive resins to above-mentioned steps 1) the salvianolic acid extracting solution that obtains adsorbs, and washes the dehydration solubility impurity earlier with water, and then with ethanol aqueous wash deresination post, the collection eluent obtains the salvianolic acid eluent;
3) to above-mentioned steps 2) the Radix Ginseng total saponins eluent that obtains carries out drying, obtains the Radix Ginseng extract powder; To above-mentioned steps 2) the salvianolic acid eluent that obtains carries out drying, obtains the Radix Salviae Miltiorrhizae extract powder;
4) with above-mentioned steps 3) the Radix Ginseng extract powder and the Radix Salviae Miltiorrhizae extract powder mixes that obtain, obtain medicine of the present invention.
When preparing ginsenoside's extracting solution in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 50-95%, is preferably 90%; The ratio of weight and number of described Radix Ginseng and ethanol water is 1: (6-15), be preferably 1: 10; Described return time is 30min-120min, is preferably 60min; When preparing the salvianolic acid extracting solution in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 10-60%, is preferably 50%; The ratio of weight and number of described Radix Salviae Miltiorrhizae and ethanol water is 1: (5-15), be preferably 1: 10; Described return time is 30min-120min, is preferably 30min;
When preparing ginsenoside's eluent described step 2), during the eluting water solubility impurity, alcoholic acid volumn concentration is less than 10% in the described ethanol water; During the eluting resin column, alcoholic acid volumn concentration is 50-90% in the described ethanol water, is preferably 60-70%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
When preparing the salvianolic acid eluent described step 2), during the eluting resin column, alcoholic acid volumn concentration is 30-90% in the described ethanol water, is preferably 40-60%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
In the described step 3), it is 50-60 ℃ that Radix Ginseng total saponins eluent and salvianolic acid eluent are carried out exsiccant temperature.
Another preparation method of medicine provided by the present invention may further comprise the steps:
1) with Radix Ginseng and Radix Salviae Miltiorrhizae according to 1: ratio of weight and number (0.08-20) mixes, with ethanol water or water the mixture of Radix Ginseng and Radix Salviae Miltiorrhizae is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain containing the mixed extract of ginsenoside and salvianolic acid;
Described Radix Ginseng be root, stem, the leaf of plant Radix Ginseng and spend at least a;
Described Radix Salviae Miltiorrhizae is the root of plant Radix Salviae Miltiorrhizae;
2) adopting macroporous adsorptive resins to above-mentioned steps 1) mixed extract that obtains adsorbs, wash the dehydration solubility impurity earlier with water, and then, collect eluent with ethanol aqueous wash deresination post, obtain containing the mixing eluent of Radix Ginseng total saponins and salvianolic acid;
3) to above-mentioned steps 2) the mixing eluent that obtains concentrates, drying, obtains the mixed extract powder of Radix Ginseng and Radix Salviae Miltiorrhizae, obtains medicine of the present invention.
When preparing mixed extract in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 30-90%, is preferably 60%; The ratio of weight and number of described Radix Ginseng and Radix Salviae Miltiorrhizae mixture and ethanol water is 1: (6-15), be preferably 1: 10; Described return time is 30-120min, is preferably 45min;
When preparation mixed eluent described step 2), during the eluting resin column, alcoholic acid volumn concentration was 30-90% in the described ethanol water, is preferably 50-70%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
In the described step 3), it is 50-60 ℃ that the mixing eluent is carried out exsiccant temperature.
Medicine of the present invention and preparation method thereof has the following advantages:
1, medicine effect material base of the present invention is clear and definite, comprises Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids that proportion compatibility is clear and definite; By experiment of rat acute myocardial infarction and myocardial ischemia experiment, the result shows, adopt the compatible drug action of Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids with the best, can effectively suppress the rat myocardium block area, improve the myocardial ischemia situation, and kept the curative effect identical with crude drug compatibility side, and drug component of the present invention is clear, and quality is controlled easily.
2, in the step of extracting Radix Salviae Miltiorrhizae total phenolic acids, take the method for direct alcohol extraction, overcome the defective that needs a large amount of condensed water in the prior art, simplified production stage, optimized working condition, free from environmental pollution, have the advantage that step is simple, easy to operate, be easy to industrialization;
3, the inventive method has avoided causing because of precipitate with ethanol in the prior art problem of salvianolic acid active component loss, has the advantage that active component loses less, finished product yield is high;
4, the inventive method has avoided in the prior art percolation to extract the long shortcoming that expends time in, and has the high advantage of extraction efficiency;
5, adopt Radix Salviae Miltiorrhizae total phenolic acids content height in the Radix Salviae Miltiorrhizae extract that the inventive method obtains, improved the utilization rate of red rooted salvia greatly;
When 6, the medicine that adopts the inventive method preparation to treat cardiovascular disease carried out industrialization production, other method that adopts can make production cost reduce greatly at present;
7, the inventive method process stabilizing, mass discrepancy is little between prepared each batch of medicine that goes out, and can pass through chromatographic fingerprinting simultaneously, and the component of Radix Ginseng total saponins in the medicine and Radix Salviae Miltiorrhizae total phenolic acids is carried out assay, can effectively control the quality of medicine of the present invention.
Description of drawings
Fig. 1 for medicinal granule of the present invention to the Electrocardiographic influence curve figure of acute myocardial ischemia rat due to the isoproterenol
Fig. 2 intervenes the idiographic flow of Chinese Small-sized Medulla Sus domestica mescenchymal stem cell vitro differentiation process experiment for medicinal granule of the present invention
When Fig. 3 induces 30d for pastille serum, intervene the situation that the MSCs cellular morphology changes
When Fig. 4 induced 30d for pastille serum, each organized the 2-DE electrophoresis detection result of cell
When Fig. 5 induces 30d for pastille serum, the situation of change of Partial Protein
Fig. 6 is the expression of albumen Lamin A/C in the MSCs atomization
Fig. 7 intervenes proteic 2-DE collection of illustrative plates in the MSCs directed differentiation process for pastille serum
Fig. 8 intervenes proteic difference variation tendency in the MSCs directed differentiation process for pastille serum
The specific embodiment
Below in conjunction with specific embodiments and the drawings, the present invention will be further described.
The preparation of the medicine of embodiment 1, treatment cardiovascular disease
The medicine of the treatment cardiovascular disease of present embodiment is made up of Radix Ginseng extract and Radix Salviae Miltiorrhizae extract, and wherein, the preparation method of Radix Ginseng extract and Radix Salviae Miltiorrhizae extract is as follows:
One, the preparation of Radix Ginseng extract
Obtain 10 purpose Radix Ginseng coarse powder after getting the root crushing screening of Radix Ginseng (Panax.ginsengC.A.Mey).Accurately take by weighing Radix Ginseng coarse powder 10kg, add the 80L volumn concentration and be 90% ethanol and carry out reflux, extract,, extraction time is 45min; Collect extracting solution, and then to add the 80L volumn concentration in residue be that 90% ethanol carries out reflux, extract,, extraction time is 45min; Repeat the said extracted process more once.Three times extracting solution are mixed, be cooled to room temperature, filter, get filtrate decompression and be concentrated into nothing alcohol flavor, obtain 2.3kg extract extractum; Get 2.3kg extract extractum add 14L water when being diluted to 20 ℃ the density of solution be 1.06g/ml, obtain 15L ginsenoside extracting solution.
(filling in resin column with polystyrene or poly-divinylbenzene is that the model of skeleton is the resin extender of HPD100 to adopt the good low pole macroporous adsorptive resins of pretreatment, this low pole macroporous adsorptive resins and HPD100 resin extender are available from Cangzhou, Hebei precious grace chemical industry company limited), 15L ginsenoside extracting solution to above-mentioned acquisition carries out separation and purification, and bed volume is 21L behind the filler.Ginsenoside's extracting solution washes resin column to the water of resin column bed volume with the flow velocity of 2bv/h (1bv/h is promptly per hour by the flow of 1 times of bed volume) with 3 times after chromatographic column absorption, remove water-solubility impurities such as polysaccharide, discards eluent; 4 times of volumn concentrations to the resin column bed volume of reuse are 70% the ethanol flow velocity eluting resin column with 1bv/h, collect eluent, obtain the Radix Ginseng total saponins eluent; With Radix Ginseng total saponins eluent concentrating under reduced pressure is thick clear paste, and thick clear paste again through 60 ℃ of constant temperature constant pressure and dries, is obtained 500g Radix Ginseng extract powder.
Adopt the HPLC method to detect the content of Radix Ginseng total saponins in the Radix Ginseng extract powder, concrete chromatographic condition is: with the octadecylsilane chemically bonded silica is filler, is mobile phase A with the acetonitrile, is Mobile phase B with water, gradient elution.Flow velocity: 1ml/min, the detection wavelength is 203nm.Theoretical cam curve is calculated by the ginsenoside Rg1 peak, is not less than 6000.Concrete condition of gradient elution is as follows:
Figure A20081022344000141
The result shows, in the above-mentioned Radix Ginseng extract powder that obtains, the quality percentage composition of Radix Ginseng total saponins is 80%, the quality percentage composition of ginsenoside Rg1 in Radix Ginseng total saponins is 3.4%, the quality percentage composition of ginsenoside Re in Radix Ginseng total saponins is 3.7%, and the quality percentage composition of ginsenoside Rb1 in Radix Ginseng total saponins is 4.1%; The quality percentage composition of ginsenoside Rf in Radix Ginseng total saponins is 0.12%.
Two, the preparation of Radix Salviae Miltiorrhizae extract
Get the root 10kg of Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Bunge.), be cut into decoction pieces, carry out reflux, extract, after adding the 100L volumn concentration and be 50% soak with ethanol 4h, extraction time is 30min; Collect extracting solution, and then to add the 100L volumn concentration in residue be that 50% ethanol carries out reflux, extract,, extraction time is 30min.Twice extracting solution is mixed, obtain the 150L Radix Salviae Miltiorrhizae extract, again this 150L Radix Salviae Miltiorrhizae extract is carried out sucking filtration, is concentrated into 50L.
Adopt macroporous adsorptive resins (the styrene type resin that with the model is HPD700 is a filler, available from Cangzhou, Hebei precious grace chemical industry company limited), the 50L Radix Salviae Miltiorrhizae extract of above-mentioned acquisition is carried out separation and purification, bed volume is 65L behind the filler.Radix Salviae Miltiorrhizae extract is after chromatographic column absorption, with 3 times to the water of resin column bed volume flow velocity flushing resin column with 2bv/h (1bv/h is promptly per hour by the flow of 1 times of bed volume), discard eluent, and then with 3 times of volumn concentrations 60% ethanol flow velocity eluting resin column with 1bv/h to the resin column bed volume, collect eluent, obtain the salvianolic acid eluent; The salvianolic acid eluent is carried out concentrating under reduced pressure, and obtaining 775g is that proportion is the thick clear paste of 1.2 (60 ℃); Thick clear paste again through 60 ℃ of constant temperature constant pressure and dries, is obtained 620g Radix Salviae Miltiorrhizae extract powder.
Adopt the HPLC method to detect the content of Radix Salviae Miltiorrhizae total phenolic acids in the Radix Salviae Miltiorrhizae extract powder, concrete chromatographic condition is: be filler with the octadecylsilane chemically bonded silica, with by the blended solution of following volume ratio as mobile phase: methanol: acetonitrile: formic acid: water=30: 10: 1: 59; Detect wavelength 286nm.Theoretical cam curve is pressed the salvianolic acid B peak and is calculated, and is not less than 2000.
Accurately take by weighing the Radix Salviae Miltiorrhizae extract powder of the above-mentioned acquisition of 2.5g, add 40ml water, use supersound process 0.5h behind the immersion 1h, get supernatant; Add 40ml water in residual residue again, supersound process 0.5h gets supernatant; Repetitive process once again.The supernatant mixing and the water of three collections are settled to 250ml, as supplying test agent.Will be for 5 times of test agent dilutions, get the measuring bottle that 2ml places 50ml, add dehydrated alcohol to 10ml, add 4ml quality percentage composition again and be 0.3% dodecyl sodium sulfate and 2ml (wherein according to the blended mixed liquor of forming by liquor ferri trichloridi and potassium ferricyanide solution of 1: 0.9 volume ratio, the quality percentage composition of liquor ferri trichloridi is 0.6%, and the quality percentage composition of potassium ferricyanide solution is 0.9%), mixed solution is shaken up, 0.1molL is used after placing 5min in the dark place -1The hydrochloric acid solution standardize solution shakes up, and after 20min was placed in the dark place, spectrophotometer 720nm detected at the place.The salvianolic acid B standard solution of getting the 1mg/mL for preparing dilutes 2,5,10,20,50 and 100 times respectively, detects the record result with said method.With concentration mgmL -1Being abscissa, is vertical coordinate with absorbance A bs value, obtains regression equation through the excel software processes.Go out the content and the productive rate of total phenolic acid according to the regression equation calculation of salvianolic acid B standard solution.
The result shows that in the above-mentioned Radix Salviae Miltiorrhizae extract powder that obtains, the quality percentage composition of Radix Salviae Miltiorrhizae total phenolic acids is 89.8%, and the productive rate of Radix Salviae Miltiorrhizae total phenolic acids is 6.6%.
Three, the preparation of the medicine of treatment cardiovascular disease
With the Radix Ginseng extract powder of 210g above-mentioned steps one preparation and the Radix Salviae Miltiorrhizae extract powder mixes of 90g above-mentioned steps two preparations, obtain medicine of the present invention.
The preparation of the medicine of embodiment 2, treatment cardiovascular disease
The preparation method of Radix Ginseng extract and Radix Salviae Miltiorrhizae extract is with embodiment 1.With 200g according to the Radix Ginseng extract powder of the method for the foregoing description 1 step 1 preparation and 20g according to the Radix Salviae Miltiorrhizae extract powder mixes that the method for the foregoing description 1 step 2 prepares, obtain medicine of the present invention.
The preparation of the medicine of embodiment 3, treatment cardiovascular disease
The preparation method of Radix Ginseng extract and Radix Salviae Miltiorrhizae extract is with embodiment 1.With 20g according to the Radix Ginseng extract powder of the method for the foregoing description 1 step 1 preparation and 400g according to the Radix Salviae Miltiorrhizae extract powder mixes that the method for the foregoing description 1 step 2 prepares, obtain medicine of the present invention.
The effect experiment of embodiment 4, treatment cardiovascular disease medicine
1, Acute Myocardial Ischemia in Rats and myocardial infarction effect experiment
Get the medicine of the foregoing description 1,2 and 3 preparations respectively, the medicinal liquid of joining for 1g/ml with normal saline carries out effect experiment.
Get 75 of SD rats (available from this laboratory animal company of Beijing agate), be divided into 5 groups at random, be respectively normal group, model group, positive controls, high dose medicament group and low-dose drugs group, 15 every group.Wherein model group, positive controls, high dose medicament group and the equal abdominal cavity of low-dose drugs group rat multi-point injection isoproterenol (ISO), every day 1 time, each 10mgkg -1Body weight is injected 2d continuously, makes up the acute myocardial ischemia rat model, and normal group gives the normal saline of same dose.After the modeling success, high dose medicament group rat is according to 320mgkg -1The dosage of body weight is irritated the drug extract that stomach gives the treatment cardiovascular disease of the foregoing description 1,2 and 3 preparations respectively; Low-dose drugs group rat is according to 64mgkg -1The dosage of body weight is irritated the drug extract that stomach gives the treatment cardiovascular disease of the foregoing description 1,2 and 3 preparations respectively; The positive controls rat is according to 200mgkg -1The dosage of body weight is irritated stomach and is given FUFANG DANSHEN DIWAN (available from sky, Tianjin Shi Li company); Model group rat and normal rats are according to 7.5mlkg -1The dosage filling stomach of body weight gives the normal saline with volume.Below respectively organize and be administered once common administration 7 days every day.
Behind last 1 administration 1h, use urethane according to 1.3gkg -1The dosage of body weight is respectively organized rat and is carried out intraperitoneal injection of anesthesia above-mentioned.Each group rat dorsal position is fixed, connect MPA2000 multiple tracks bio signal analytical system (II leads), the normal ECG in the rat 5min respectively organized in record, and the unusual rat of generation is discarded need not.After waiting to stablize, except that normal rats is given the normal saline, all the other respectively organize the equal abdominal cavity of rat multi-point injection isoproterenol (ISO), and injection measurement is 10mgkg -1Body weight.Behind the record injection ISO 0.5,1,2,5,10,15 and respectively organize the electrocardiogram of rat during 20min, observe the variation of J point (terminal point of QRS wave group and T ripple junction) respectively.With the mV number of its reduction as index, electrocardiogram J point value (mV) before each time point electrocardiogram J point value (mV)-lumbar injection ISO behind Δ J (electrocardiogram J point changing value)=lumbar injection ISO.
Possess one of following condition person and be judged as rat heart muscle ischemia positive criteria:
1) J point skew 〉=0.1mV downward or upward;
2) the T wave height is alarmmed, and surpasses with leading 1/2 of R ripple;
3) the T wave height is alarmmed the displacement of companion J point.
Line with QRS complex wave starting point is made isoelectric line, and the degrees of offset of ordering with J is a diagnosis basis, and selects the index of the millivolt average of heart beating calculating J point change in 2 seconds as degree of myocardial ischemia.
The drug extract of the treatment cardiovascular disease of embodiment 1 influences the result as shown in Figure 1 to the acute myocardial ischemia rat due to the isoproterenol (ISO) is Electrocardiographic.As can be seen from the figure, after each organized rats by intraperitoneal injection ISO, significant change all took place in electrocardiogram J point, after the of short duration rising, along with the prolongation of time, descended gradually; The inductive rat electrocardiogram J point of antagonism ISO raises and does in order to administration group optimum, and each time point Δ J of administration group rat compares with the model group rat, and difference is (P＜0.05) significantly.
Surveyed after the electrocardiogram, give embodiment 1 medicine respectively organize SD rat 1h behind ip ISO, open the abdominal cavity and get blood from postcava, the wherein content of LDH, CK, SOD and MDA is measured in the freezing preservation of separation of serum.The result is as shown in table 1.
LDH, CK, SOD and MDA value in the table 1 acute myocardial ischemia rat blood serum (x ± s, n=9)
Figure A20081022344000181
Compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with model group.
The result shows, compares with normal group, and model group rat LDH and CK value significantly raise (P＜0.01), and SOD value is reduction (P＜0.05) significantly, MDA value extremely significantly raise (P＜0.001).Compare with model group, the LDH of administration group, CK and MDA value all significantly reduce (P＜0.05).For LDH, high dose group and low dose group all are better than positive controls, and for CK, the high dose group effect is best, and low dose group and positive controls are close, and for SOD and MDA, three's effect is close.
After getting the blood agglomeration bundle, the heart of SD rat is respectively organized in taking-up rapidly, after cleaning up with normal saline, reject non-cardiac muscular tissue, blot with filter paper, weigh, in refrigerator freezing 30 minutes, after the taking-up ventricle is cut into the thick myocardium sheet of 0.1cm, place nitro blue tetrazolium (NBT) solution, temperature is incubated dyeing 15min in 37 ℃ of water-baths, the non-orchid of cardiac muscle is dyed district's (infarct) downcut, the ratio that claims weight in wet base, the non-orchid of calculating myocardium to dye district's weight and total cardiac weight is myocardial infarction area (myocardial infarction area=(infarct heart heavy/total cardiac weight) * 100%).The result is as shown in table 2.
Table 2 acute myocardial ischemia rat heart infarct size (x ± s, n=9)
Compare * P＜0.05 * * * P＜0.001 with model group.
The result shows, compares the cardiac infarction area of model group rat significantly raise (P＜0.001) with normal group; Compare with model group, high dose medicament group rat myocardium block area obviously reduces, and has significant difference (P＜0.05).
2, the drug extract of treatment cardiovascular disease promotes Chinese Small-sized Medulla Sus domestica mescenchymal stem cell (MSCs) vitro differentiation process experiment
Concrete experiment flow as shown in Figure 2.
Respectively with the drug solution of the foregoing description 1,2 and 3 with 10mlkg -1The dosage of body weight carries out gastric infusion to the SD rat, irritates stomach every day 2 times, and successive administration 3d behind the last administration 1h, gets the serum of rat, adds in the culture medium, makes 4% pastille serum.
The mesenchymal stem cells MSCs of Chinese Small-sized pig (MSCs) (available from animal housing of BJ Union Hospital) is incubated in the DMEM/F12 culture medium behind extraction, purification, makes cell density reach 100/100 μ L.Chinese Small-sized pig MSCs is divided into three groups of A, B, C, and the A group is MSCs propagation group; The B group is induced group for 5-aza, promptly adds U-18496 (5-aza) (available from Shanghai Sangon Biological Engineering Technology And Service Co., Ltd) in incubation, and making its final concentration in culture medium is 10 μ mol/L; The C group promptly adds 5-aza for the pastille serum group in incubation, making its final concentration in culture medium is 10 μ mol/L, adds 4% pastille serum of above-mentioned preparation simultaneously.
Give embodiment 1 medicine respectively organize cell culture 30d the time cellular morphology as shown in Figure 3.Wherein, Fig. 3 A, 3B and 3C represent above-mentioned A, B, three experimental grouies of C respectively.The result shows, the pastille serum that in culture medium, adds above-mentioned preparation, cellular morphology is changed, in conjunction with single situation that cellular morphology changes when inducing the MSCs directed differentiation with 5-aza, show tentatively that pastille serum is induced at 5-aza to play the effect that suppresses cell proliferation, promotes cell differentiation in the MSCs directed differentiation process.Induce at 5-aza with the pastille serum of the medication preparation of embodiment 2 or 3 and also can play the effect that suppresses cell proliferation, promotes cell differentiation in the MSCs directed differentiation process.
When medicine above-mentioned that gives embodiment 1 respectively organized cell culture 30d, extract albumen respectively, carry out the 2-DE electrophoresis, it is as follows to carry out the electrophoretic actual conditions of proteome analysis 2-DE: albumen applied sample amount: 150 μ g; 2-DE deposition condition and parameter: the linear adhesive tape (17cm) of pH 5-8IPG; 10kV focuses on 60kVh down; 12%PAGE is used for protein isolate, the about 8h of constant current electrophoresis (30mA/gel) operation.Silver dyes and detects the gel protein point, and the result as shown in Figure 4.Wherein, Fig. 4 A, 4B and 4C represent above-mentioned A, B, three experimental grouies of C respectively.The result shows that pastille serum can be intervened proteic expression in the MSCs atomization.
Above-mentioned when respectively organizing cell culture 30d, the situation of change of Partial Protein as shown in Figure 5.Twice repetition established in experiment.Among Fig. 5, abscissa is represented different albumen, only lists significance in the table 3 and changes albumen; Vertical coordinate is represented each proteic expression.
Table 3 pastille serum is intervened differential protein evaluation situation in the MSCs atomization
Figure A20081022344000201
As can be seen from Figure 5, similar Lamin A/C is not expressed before the MSCs differentiation, can detect this proteic expression after the differentiation, under the effect of pastille serum, this protein expression presents about 5.7 times rise trend, shows that pastille serum can promote the atomization of MSCs; Antioxidase 2 presents in the MSCs atomization and increases progressively trend, and after pastille serum acts on the MSCs atomization, has suppressed the expression of antioxidase 2.
The expression of Lamin A/C in the MSCs atomization as shown in Figure 6.From Fig. 6 also as can be seen, similar Lamin A/C is not expressed before the MSCs differentiation, can detect this proteic expression after the differentiation, under the effect of pastille serum, this protein expression presents rise trend, shows that pastille serum can promote the atomization of MSCs.
The albumen 2-DE collection of illustrative plates of intervening different time points (6d and 30d) in the MSCs directed differentiation process with the pastille serum of the medication preparation of embodiment 1 as shown in Figure 7.Wherein, proteic 2-DE collection of illustrative plates when proteic 2-DE collection of illustrative plates when Fig. 7 A intervenes MSCs directed differentiation 6d for pastille serum, Fig. 7 B are intervened MSCs directed differentiation 30d for pastille serum.By comparison, can analyze at pastille serum and intervene proteic variation tendency in the atomization the 2-DE collection of illustrative plates of these two time points.Listed among Fig. 8 in twice repeated experiments, some significances changed proteic expression before and after the MSCs differentiation was induced in the intervention of pastille serum.Among Fig. 8, abscissa is represented different albumen, and each proteic numbering and title are as shown in table 4; Vertical coordinate is represented each proteic expression.6C1 represents experiment for the first time, and the expression during pastille serum group 6d, 6C2 are represented experiment for the second time, expression during pastille serum group 6d, 30C1 are represented experiment for the first time, the expression during pastille serum group 30d, 30C2 represents experiment for the second time, the expression during pastille serum group 30d.
Table 4 directed differentiation process Identification of Fusion Protein result
Figure A20081022344000211
Above experimental result shows, intervene in the MSCs directed differentiation process at pastille serum, Partial Protein participates in cell proliferation or atomization according to its molecular structure characteristics and in intracellular distribution situation by different signal pathways, and causes thus presenting difference in the above-mentioned multiple protein expression.Induce down at 5-aza, MSCs is in-vitro directed to be divided in the myocardial cell process, expresses the atomization that the albumen that presents difference has participated in MSCs, and the differentiation that pastille serum and 5-aza synergism can be induced MSCs embodies in the expression of associated protein to some extent.With the pastille serum of the medication preparation of embodiment 2 or 3 and the differentiation that the 5-aza synergism also can be induced MSCs.
3, the inducing bone mesenchymal differentiation of stem cells becomes the gene expression of cardiac-like muscle cell to detect
Existing many bibliographical information 5-aza can induce BMMSCs to break up to myocardial cell, and the mechanism of its differentiation may some cytosine demethylation causes in the cell DNA owing to 5-aza can make.
Get MSCs cell after 5-aza induces in the above-mentioned steps 2 (be B group cell) and the MSCs cell (being C group cell) after the pastille serum of the medication preparation of 5-aza and embodiment 1 is induced 30 days, extract its total RNA respectively, and reverse transcription is cDNA, with this cDNA is template, designs primer PCR increase following 10 gene: Il1a, Pla2g2a, Ccl20, Ccl2, Mmp9, IL6, Sncg, 2 ' 5 '-AS, Pem, 3 α HSD respectively.Concrete primer is as follows:
Figure A20081022344000221
According to rise, the downward modulation of gene expression, and the physiological function of time point, acting duration and the gene of pastille serum inducing action is divided into five kinds of binding modes with pastille serum inducing action mode: component is induced mode, the omnidistance rise of component to induce mode for a long time, is promoted model of action, model of action that suppresses the MSCs canceration that the MSCs metabolism is grown and the model of action that strengthens the basic indication of cell life.
1) component is induced mode for a long time: gene Il1a, Ccl20, Ccl2, Pla2g2a and Mmp9 are similar to the responsive mode of pastille serum, are active phase with 10 days, 20 days time points.Variable quantity with 10 days time point gene Il1a, Ccl20, Ccl2, Pla2g2a and Mmp9 compares, and overall trend is that the 5-aza group is similar to or is better than the pastille serum group; But compare with continuous action time length, the pastille serum group is in the time of 10 days, 20 days, and gene Il1a, Ccl20, Ccl2, Pla2g2a and Mmp9 have the expression ascendant trend, obviously are better than 5-aza and induce group.The medicine that above-mentioned steps three preparations are described has slower, more stable effect.
2) component is omnidistance raises that to induce mode: Mmp9 (matrix metal peptidase 9) be a kind of proteolytic enzyme, experiment confirm is arranged, MMP9 overexpression in the atherosis unstability speckle of human artery, increased activity, and can decompose collagen fragment in the atheromatous plaque.Pastille serum is induced under the stimulation, the Mmp9 gene is all presented mileometer adjustment and is reached in 10 days to 40 days time, when the medicine that shows above-mentioned steps three preparation is used for the acute myocardial infarction treatment, the stimulation Mmp9 gene expression of meeting persistence is raised, act on the atheromatous plaque place that myocardial infarction produces, make the substrate degradation of speckle, thereby be the myocardial cell creation advantageous conditions that newborn myocardial cell substitutes the necrosis of speckle place.
3) promote the model of action that the MSCs metabolism is grown: Il6 (interleukin-6) gene quantification testing result shows that Il6 gene expression obviously raises when having only 10 days time points of pastille serum group.Illustrate that pastille serum has tangible intervention effect to the Il6 gene, and the Best Times that plays a role is 10 days.When 20 days, 30 days and 40 days, Il6 gene expression all presents downward modulation in all samples, in the time of 30 days downward modulation the most obvious, consider that this moment, apoptosis began.
4) suppress the model of action of MSCs canceration: Sncg (homotype nucleoprotein γ) gene quantification testing result shows, 5-aza induces that the Sncg gene all had obvious expression decline in group and the pastille serum group in the time of 30 days.Sncg genovariation is that multiple cancer worsens key factor, and is relevant with growth, infiltration, transfer and the prognosis of cancerous cell.
5) model of action of enhancing cell life basis indication: Pem (polymorphic epithelium mucoitin) gene is the intracellular signal transduction molecule, does not express in becoming somatic cell, but expression is arranged in sexual cell, breaks up relevant with gonad development with embryonic cell; 2 ' 5 '-AS (2 ' 5 ' oligo-adenylate synthetase) gene is the media that interferon plays a role, and has antiviral, suppresses the synthetic and biological functions such as cell growth, adjusting immunoreation of DNA; 3 α HSD (3 α-hydroxyl-steroid dehydrogenase) are one of enzymes initial in the steroid metabolism approach, TOTAL BILE ACID TBA in the serum (TBA) is that a class has 3 alpha-hydroxy steroid derivatives, under 3 α HSD catalysis, dehydrogenation generates corresponding 3-ketosteroid, in this process with coenzyme NAD+be reduced to NADH+H+, further regulate the activity of glucose-6-phosphate dehydrogenase, the metabolic cycles of involved in sugar.
Analyze the function of above each gene and find, the 10 big class basi gene functions of keeping with organism life all have and relate to.Interpretation of result shows, Il1a, Pla2g2a, Ccl20, Ccl2, these 5 genes of Mmp9 may have been brought into play major function inducing differentiation MSCs to become on the mechanism of action of cardiac-like muscle cell, and other 5 genes are promoting the MSCs metabolism to grow, suppress the canceration process of MSCs, strengthen and bringing into play complementary function aspect the indication of cell life basis respectively.Therefore think that the process that the drug-induced MSCs of above-mentioned steps three preparations is divided into cardiac-like muscle cell is the result of multi-functional, many networks, polygenic coordinative role.
Immunofluorescence result shows, the conversion ratio of inducing that 5-aza induces group to induce MSCs to be divided into cardiac-like muscle cell is higher than the pastille serum group, but the gene quantification testing result shows, the expression change of the key gene of pastille serum group lasts longer than 5-aza and induces group, consider that 5-aza inducing action produce effects is fast, can bring into play its effect at short notice, and the pastille serum group is on the contrary, show the foregoing description 1, the medicine of 2 or 3 preparations may be bigger to the material base-gene performance scope of genetic expression, the inducing action that doubles, to reach the required time of produce effects longer by measuring matter in this effect.So, think that the drug-induced MSCs of the foregoing description 1,2 or 3 preparations is divided into the effect of cardiac-like muscle cell, The apparent phenomenon is obvious not as 5-aza, but the efficient of improving of the nature basis of effect is better than 5-aza.
The preparation of the medicinal granule of embodiment 5, treatment cardiovascular disease
One, the preparation of the medicinal granule of treatment cardiovascular disease
Get the Radix Ginseng extract powder 100g of the foregoing description 1 step 1 preparation and the Radix Salviae Miltiorrhizae extract powder 10g of the foregoing description 1 step 2 preparation, with the two mix homogeneously, add 360g dextrin (weight that adds dextrin is Radix Ginseng extract powder and Radix Salviae Miltiorrhizae extract powder weight sum 3 times) and 240g cane sugar powder (weight that adds cane sugar powder is Radix Ginseng extract powder and Radix Salviae Miltiorrhizae extract powder weight sum 2 times) again, mix homogeneously, being made for granularity is 16 purpose drug particles, under 60 ℃ of conditions drug particles is carried out drying, the medicinal granule of the cardiovascular disease that obtains medical treatment.
Two, zoopery
Concrete experimental technique is with embodiment 4.The result shows that the medicinal granule of present embodiment is identical with the effect of the medicine of embodiment 1,2 and 3 to the therapeutic effect of rat acute myocardial infarction and myocardial ischemia.
The preparation of the drug injection of embodiment 6, treatment cardiovascular disease
One, the preparation of Radix Ginseng extract
(pollen of Panax.ginsengC.A.Mey is broken to obtain 10 purpose Flos Ginseng coarse powder after sieving to get Radix Ginseng.Accurately take by weighing Flos Ginseng's coarse powder 150g, add the 1500ml volumn concentration and be 90% ethanol and carry out reflux, extract,, extraction time is 45min; Collect extracting solution, and then to add the 1500ml volumn concentration in residue be that 90% ethanol carries out reflux, extract,, extraction time is 45min.Extracted twice liquid is mixed, be cooled to room temperature, filter, get filtrate decompression and be concentrated into nothing alcohol flavor, obtain 32g extract extractum; Get 32g extract extractum add 90ml water when being diluted to 20 ℃ the density of solution be 1.06g/ml, obtain 96ml ginsenoside extracting solution.
(filling with polystyrene or poly-divinylbenzene in resin column is that the skeleton model is the resin extender of HPD700 to adopt the good low pole macroporous adsorptive resins of pretreatment, this low pole macroporous adsorptive resins and HPD700 resin extender are available from Cangzhou, Hebei precious grace chemical industry company limited), 96ml ginsenoside extracting solution to above-mentioned acquisition carries out separation and purification, and bed volume is 117ml behind the filler.Ginsenoside's extracting solution washes resin column to the water of resin column bed volume with the flow velocity of 2bv/h (1bv/h is promptly per hour by the flow of 1 times of bed volume) with 3 times after chromatographic column absorption, remove water-solubility impurities such as polysaccharide, discards eluent; 4 times of volumn concentrations to the resin column bed volume of reuse are 60% the ethanol flow velocity eluting resin column with 1bv/h, collect eluent, obtain the Radix Ginseng total saponins eluent; With Radix Ginseng total saponins eluent concentrating under reduced pressure is thick clear paste, with thick clear paste again through 60 ℃ of constant temperature constant pressure and dries, obtain 9g Flos Ginseng extract powder (wherein the content of Radix Ginseng total saponins reaches 83% (assay method is with embodiment 1)), the quality percentage composition of ginsenoside Rg1 in Radix Ginseng total saponins is 2.3%, the quality percentage composition of ginsenoside Re in Radix Ginseng total saponins is 2.6%, and the quality percentage composition of ginsenoside Rb1 in Radix Ginseng total saponins is 3.1%; The quality percentage composition of ginsenoside Rf in Radix Ginseng total saponins is 0.015%.
Two, the preparation of Radix Salviae Miltiorrhizae extract
Get the root 10kg of Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Bunge.), be cut into decoction pieces, decoction pieces was pulverized 10 mesh sieves make the Radix Salviae Miltiorrhizae coarse powder, carry out reflux, extract, after adding the 100L volumn concentration and be 50% soak with ethanol 4h, extraction time is 30min; Collect extracting solution, and then to add the 100L volumn concentration in residue be that 50% ethanol carries out reflux, extract,, extraction time is 30min.Twice extracting solution is mixed, obtain the 150L Radix Salviae Miltiorrhizae extract, again this 150L Radix Salviae Miltiorrhizae extract is carried out sucking filtration, is concentrated into 50L.
Adopt macroporous adsorptive resins (the styrene type resin that with the model is HPD300 is a filler, available from Cangzhou, Hebei precious grace chemical industry company limited), the 50L Radix Salviae Miltiorrhizae extract of above-mentioned acquisition is carried out separation and purification, bed volume is 65L behind the filler.Radix Salviae Miltiorrhizae extract is after chromatographic column absorption, with 3 times to the water of resin column bed volume flow velocity flushing resin column with 2bv/h (1bv/h is promptly per hour by the flow of 1 times of bed volume), discard eluent, and then with 3 times of volumn concentrations 40% ethanol flow velocity eluting resin column with 1bv/h to the resin column bed volume, collect eluent, obtain the salvianolic acid eluent; The salvianolic acid eluent is carried out concentrating under reduced pressure, and obtaining 820g is that proportion is the thick clear paste of 1.2 (60 ℃); Thick clear paste again through 60 ℃ of constant temperature constant pressure and dries, is obtained 660g Radix Salviae Miltiorrhizae extract powder (wherein the productive rate of Radix Salviae Miltiorrhizae total phenolic acids is 6.6%).After testing, in the Radix Salviae Miltiorrhizae extract powder, the content of Radix Salviae Miltiorrhizae total phenolic acids is 94.7% (assay method is with embodiment 1).
Three, the preparation of the injection of treatment cardiovascular disease
Get the Radix Ginseng extract powder 10g of above-mentioned steps one preparation and the Radix Salviae Miltiorrhizae extract powder 200g of above-mentioned steps two preparations, add 630ml water for injection again, stir, under 4 ℃ of conditions, leave standstill 24h.Draw supernatant, use the ratio of active carbon/100ml supernatant in supernatant, to add the injection active carbon, be incubated 30min under 40 ℃ of conditions, with 0.22 μ m filtering with microporous membrane in the 0.05g injection; Get filtrate, adding water for injection again, to make the gross weight of mixed liquor be 840g, stir, and the ampoule embedding, pressure sterilizing is 30 minutes under 115 ℃ of conditions, packing, the drug injection of the cardiovascular disease that obtains medical treatment.
Four, zoopery
Concrete experimental technique is with embodiment 4.The result shows that the drug injection of present embodiment is identical with the effect of the medicine of embodiment 1,2 and 3 to the therapeutic effect of rat acute myocardial infarction and myocardial ischemia.
The preparation of the medicament sustained-release tablets of embodiment 7, treatment cardiovascular disease
One, the preparation of Radix Ginseng extract
Accurately take by weighing the blade 8kg that gets Radix Ginseng (Panax.ginsengC.A.Mey), add the 64L volumn concentration and be 90% ethanol and carry out reflux, extract,, extraction time is 45min; Collect extracting solution, and then to add the 64Lml volumn concentration in residue be that 90% ethanol carries out reflux, extract,, extraction time is 45min; Repeat the said extracted process more once.Three times extracting solution are mixed, be cooled to room temperature, filter, get filtrate decompression and be concentrated into nothing alcohol flavor, obtain 1.15kg extract extractum; Get 1.15kg extract extractum add 4.1L water when being diluted to 20 ℃ the density of solution be 1.06g/ml, obtain 4.4L ginsenoside extracting solution.
(with polystyrene or poly-divinylbenzene is skeleton to adopt the good low pole macroporous adsorptive resins of pretreatment, filling model in resin column is the resin extender of S-8, available from Cangzhou, Hebei precious grace chemical industry company limited), 4.4L ginsenoside extracting solution to above-mentioned acquisition carries out separation and purification, and bed volume is 5.7L behind the filler.Ginsenoside's extracting solution is after chromatographic column absorption, with 3 times of volumn concentrations 5% ethanol with the flow velocity flushing resin column of 2bv/h (1bv/h is promptly per hour by the flow of 1 times of bed volume) to the resin column bed volume, remove water-solubility impurities such as polysaccharide, discard eluent; 4 times of volumn concentrations to the resin column bed volume of reuse are 70% the ethanol flow velocity eluting resin column with 1bv/h, collect eluent, obtain the Radix Ginseng total saponins eluent; With Radix Ginseng total saponins eluent concentrating under reduced pressure is thick clear paste, with the thick clear paste of 450g that obtains again through 60 ℃ of constant temperature constant pressure and dries, obtain 320g Radix Ginseng extract powder (wherein the content of Radix Ginseng total saponins reaches 81% (assay method is with embodiment 1)), the quality percentage composition of ginsenoside Rg1 in Radix Ginseng total saponins is 2.1%, the quality percentage composition of ginsenoside Re in Radix Ginseng total saponins is 2.6%, and the quality percentage composition of ginsenoside Rb1 in Radix Ginseng total saponins is 2.5%; The quality percentage composition of ginsenoside Rf in Radix Ginseng total saponins is 0.03%.
Two, the preparation of Radix Salviae Miltiorrhizae extract
Get the root 10kg of Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Bunge.), be cut into decoction pieces, decoction pieces was pulverized 10 mesh sieves make the Radix Salviae Miltiorrhizae coarse powder, carry out reflux, extract, after adding the 100L volumn concentration and be 50% soak with ethanol 4h, extraction time is 30min; Collect extracting solution, and then to add the 100L volumn concentration in residue be that 50% ethanol carries out reflux, extract,, extraction time is 30min.Twice extracting solution is mixed, obtain the 150L Radix Salviae Miltiorrhizae extract, again this 150L Radix Salviae Miltiorrhizae extract is carried out sucking filtration, is concentrated into 50L.
Adopt macroporous adsorptive resins (the styrene type resin that with the model is HPD300 is a filler, available from Cangzhou, Hebei precious grace chemical industry company limited), the 50L Radix Salviae Miltiorrhizae extract of above-mentioned acquisition is carried out separation and purification, bed volume is 63L behind the filler.Radix Salviae Miltiorrhizae extract is after chromatographic column absorption, with 3 times to the water of resin column bed volume flow velocity flushing resin column with 2bv/h (1bv/h is promptly per hour by the flow of 1 times of bed volume), discard eluent, and then with 3 times of volumn concentrations 50% ethanol flow velocity eluting resin column with 1bv/h to the resin column bed volume, collect eluent, obtain the salvianolic acid eluent; The salvianolic acid eluent is carried out concentrating under reduced pressure, and obtaining 812g is that proportion is the thick clear paste of 1.2 (60 ℃); Thick clear paste again through 60 ℃ of constant temperature constant pressure and dries, is obtained 640g Radix Salviae Miltiorrhizae extract powder (wherein the productive rate of Radix Salviae Miltiorrhizae total phenolic acids is 6.4%).After testing, in the Radix Salviae Miltiorrhizae extract powder, the content of Radix Salviae Miltiorrhizae total phenolic acids is 91.6% (assay method is with embodiment 1).
Three, the preparation of the medicament sustained-release tablets of treatment cardiovascular disease
Get the Radix Ginseng extract powder 50g of above-mentioned steps one preparation and the Radix Salviae Miltiorrhizae extract powder 50g of above-mentioned steps two preparations, with the two mix homogeneously, add 100g hydroxypropyl emthylcellulose (specification is SH4000) (weight that adds hydroxypropyl emthylcellulose is the weight sum of Radix Ginseng extract powder and Radix Salviae Miltiorrhizae extract powder) and 100g lactose (weight that adds lactose is the weight sum of Radix Ginseng extract powder and Radix Salviae Miltiorrhizae extract powder) again, mix homogeneously, being made for granularity is 20 purpose granules, under 60 ℃ of conditions granule is carried out drying, add the 1.5g magnesium stearate again, make magnesium stearate be overlying on Manufactured particle surface (weight of magnesium stearate account for slow releasing tablet gross weight 0.5%), carry out tabletting at last again, the medicament sustained-release tablets of the cardiovascular disease that obtains medical treatment, every heavy 1g.
Four, zoopery
Concrete experimental technique is with embodiment 4.The result shows that the medicament sustained-release tablets of present embodiment is identical with the effect of the medicine of embodiment 1,2 and 3 to the therapeutic effect of rat acute myocardial infarction and myocardial ischemia.
Embodiment 8, a kind of preparation for the treatment of the medicinal tablet of cardiovascular disease
One, the preparation of Radix Ginseng and Radix Salviae Miltiorrhizae mixed extract
250g Radix Ginseng Rubra decoction pieces is mixed with the 250g salvia piece, add the 4000ml volumn concentration and be 50% ethanol and carry out reflux, extract,, extraction time is 45min, collect extracting solution, and then to add the 3500ml volumn concentration in residue be that 50% ethanol carries out reflux, extract,, and extraction time is 45min; Repeat the said extracted process more once.Three times extracting solution are mixed, be cooled to room temperature, filter, get filtrate decompression and be concentrated into nothing alcohol flavor, obtain 127g extract extractum; Get 127g extract extractum adding 600ml water and dilute, obtain the 640ml mixed extract.
(filling in resin column with polystyrene or poly-divinylbenzene is that the model of skeleton is the resin extender of HPD100 to adopt the good low pole macroporous adsorptive resins of pretreatment, available from Cangzhou, Hebei precious grace chemical industry company limited), 640ml mixed extract to above-mentioned acquisition carries out separation and purification, and bed volume is 790ml behind the filler.Mixed extract washes resin column to the water of resin column bed volume with the flow velocity of 2bv/h (1bv/h is promptly per hour by the flow of 1 times of bed volume) with 7 times after chromatographic column absorption, remove water-solubility impurity, discards eluent; 3 times of volumn concentrations to the resin column bed volume of reuse are 40% ethanol with the flow velocity eluting resin column of 2bv/h once, with 3 times of volumn concentrations 65% ethanol once with the flow velocity eluting resin column of 2bv/h to the resin column bed volume, collect twice eluent and, obtain the mixing eluent of Radix Ginseng total saponins and salvianolic acid its merging; The mixing eluent of Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids is carried out drying, obtain the mixed extract powder of 22g Radix Ginseng and Radix Salviae Miltiorrhizae.Wherein, the content of Radix Ginseng total saponins is 31.3%, the quality percentage composition of ginsenoside Rg1 in Radix Ginseng total saponins is 4.1%, the quality percentage composition of ginsenoside Re in Radix Ginseng total saponins is 4.3%, the quality percentage composition of ginsenoside Rb1 in Radix Ginseng total saponins is 3.9%, and the quality percentage composition of ginsenoside Rf in Radix Ginseng total saponins is 0.4%; The content of Radix Salviae Miltiorrhizae total phenolic acids is 33.7% (assay method is with embodiment 1).
Two, the preparation of the medicinal tablet of treatment cardiovascular disease
Take by weighing the Radix Ginseng of 22g above-mentioned steps one preparation and the mixed extract powder of Radix Salviae Miltiorrhizae, add 22g starch (adding the weight of starch and being equal in weight of mixed extract powder) and 11g lactose (weight that adds lactose is half of mixed extract powder weight), mix homogeneously, making granularity is 16 purpose granules, drying, tabletting, the medicinal tablet of the cardiovascular disease that obtains medical treatment.
Four, zoopery
Concrete experimental technique is with embodiment 4.The result shows that the medicinal tablet of present embodiment is identical with the effect of the medicine of embodiment 1,2 and 3 to the therapeutic effect of rat acute myocardial infarction and myocardial ischemia.
Embodiment 9, a kind of preparation and effect experiment thereof for the treatment of the medicine decoction of cardiovascular disease
One, the preparation of the medicine decoction of treatment cardiovascular disease
Getting the Radix Ginseng decoction pieces mixes by 7: 3 weight ratio with salvia piece, adding the 800ml decocting in the 100g mixture that obtains boiled 1 hour, filter, get decoction liquor and filtering residue respectively, in filtering residue, add the 600ml decocting again and boiled 1 hour, twice decoction liquor is merged, filter, concentrate, obtain 1100ml filtrate, this filtrate is the medicine decoction of treatment cardiovascular disease.In this decoction, the content of Radix Ginseng total saponins is 3.4mg/ml, ginsenoside Rg1's content is the content 0.18mg/ml of Rg1, and the content of ginsenoside Re in Radix Ginseng total saponins is 0.23mg/ml, and the content of ginsenoside Rb1 in Radix Ginseng total saponins is 0.14mg/ml; The content of Radix Salviae Miltiorrhizae total phenolic acids is 1.1mg/ml (assay method is with embodiment 1).
Two, the effect experiment of the medicine decoction of treatment cardiovascular disease
Method according to the foregoing description 4 makes up the acute myocardial ischemia rat model, and be divided into model group and administration group, administration group rat is irritated the medicine decoction that stomach gives the treatment cardiovascular disease of above-mentioned steps one preparation according to the dosage of 5.0ml/kg body weight, model group gives the normal saline of same dose, investigate this medicine to the influence of acute myocardial ischemia rat heart infarct size due to the isoproterenol (ISO) (x ± s, n=9).The result is as shown in table 5.
The medicine decoction of table 5 treatment cardiovascular disease is to the influence of acute myocardial ischemia rat heart infarct size
Figure A20081022344000291
Compare * P＜0.05 * * P＜0.01 with model group
The result shows that the administration group can effectively suppress the heart infarct size to a certain extent.

Claims (14)

1, a kind of medicine, the raw material that its active component is made up of Radix Ginseng and Radix Salviae Miltiorrhizae is made;
Described Radix Ginseng be root, stem, the leaf of Radix Ginseng plant and spend at least a;
Described Radix Salviae Miltiorrhizae is the root of Radix Salviae Miltiorrhizae plant;
The ratio of weight and number of described Radix Ginseng and Radix Salviae Miltiorrhizae is 1: (0.08-20).
2, a kind of medicine, its active component are Radix Ginseng extract and Radix Salviae Miltiorrhizae extract; The ratio of weight and number of described Radix Ginseng extract and Radix Salviae Miltiorrhizae extract is 1: (0.1-20);
In the described Radix Ginseng extract, the quality percentage composition of Radix Ginseng total saponins is greater than 50%, is preferably more than to equal 80%; In the described Radix Salviae Miltiorrhizae extract, the quality percentage composition of salvianolic acid is greater than 50%, is preferably more than to equal 80%.
3, medicine according to claim 2, it is characterized in that: in the described Radix Ginseng total saponins, the quality percentage composition of ginsenoside Rg1 in Radix Ginseng total saponins is more than or equal to 2%, the quality percentage composition of ginsenoside Re in Radix Ginseng total saponins is more than or equal to 2.5%, and the quality percentage composition of ginsenoside Rb1 in Radix Ginseng total saponins is more than or equal to 2%.
4, according to arbitrary described medicine among the claim 1-3, it is characterized in that: described medicine is any one in following three kinds of medicines: treat and/or prevent angiopathy medicine, promote the medicine of mesenchymal stem cells MSCs differentiation to become the medicine of cardiac-like muscle cell with the inducing bone mesenchymal differentiation of stem cells.
5, medicine according to claim 4 is characterized in that: described angiopathy is cardiovascular disease, cerebrovascular disease or peripheral vascular disease; Described cardiovascular disease is coronary heart disease, angina pectoris, myocardial ischemia or anoxia or myocardial infarction; Described cerebrovascular disease is ischemic cerebrovascular or vascular dementia; Described peripheral vascular disease is rhomboembolia type cerebral vasculitis or phlebothrombosis.
6, according to arbitrary described medicine among the claim 1-5, it is characterized in that: the dosage form of described medicine is tablet, granule, capsule, drop pill, suppository, oral cavity disintegration tablet, injection, infusion solution, slow-release tablet agent, slow controlled release micro pill, aerosol or inhalant.
7, according to arbitrary described medicine among the claim 2-6, it is characterized in that: described Radix Ginseng extract and Radix Salviae Miltiorrhizae extract are prepared as follows:
1) with ethanol water or water Radix Ginseng is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain ginsenoside's extracting solution; With ethanol water Radix Salviae Miltiorrhizae is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain the salvianolic acid extracting solution;
2) adopting macroporous adsorptive resins to above-mentioned steps 1) ginsenoside's extracting solution of obtaining adsorbs, first water or ethanol water eluting water solubility impurity, and then with ethanol aqueous wash deresination post, the collection eluent obtains the Radix Ginseng total saponins eluent; Adopting macroporous adsorptive resins to above-mentioned steps 1) the salvianolic acid extracting solution that obtains adsorbs, and washes the dehydration solubility impurity earlier with water, and then with ethanol aqueous wash deresination post, the collection eluent obtains the salvianolic acid eluent;
3) to above-mentioned steps 2) the Radix Ginseng total saponins eluent that obtains carries out drying, obtains Radix Ginseng extract; To above-mentioned steps 2) the salvianolic acid eluent that obtains carries out drying, obtains Radix Salviae Miltiorrhizae extract.
8, medicine according to claim 7 is characterized in that: when preparing ginsenoside's extracting solution in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 50-95%, is preferably 90%; Described return time is 30min-120min, is preferably 60min;
When preparing the salvianolic acid extracting solution in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 10-60%, is preferably 50%; Described return time is 30min-120min, is preferably 30min;
When preparing ginsenoside's eluent described step 2), during the eluting water solubility impurity, alcoholic acid volumn concentration is less than 10% in the described ethanol water; During the eluting resin column, alcoholic acid volumn concentration is 50-90% in the described ethanol water, is preferably 60-70%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
When preparing the salvianolic acid eluent described step 2), during the eluting resin column, alcoholic acid volumn concentration is 30-90% in the described ethanol water, is preferably 40-60%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
In the described step 3), it is 50-60 ℃ that Radix Ginseng total saponins eluent and salvianolic acid eluent are carried out exsiccant temperature.
9, according to arbitrary described medicine among the claim 2-6, it is characterized in that: described Radix Ginseng extract and Radix Salviae Miltiorrhizae extract are prepared as follows:
1) with Radix Ginseng and Radix Salviae Miltiorrhizae according to 1: ratio of weight and number (0.08-20) mixes, with ethanol water or water the mixture of Radix Ginseng and Radix Salviae Miltiorrhizae is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain containing the mixed extract of ginsenoside and salvianolic acid;
Described Radix Ginseng be root, stem, the leaf of Radix Ginseng plant and spend at least a;
Described Radix Salviae Miltiorrhizae is the root of Radix Salviae Miltiorrhizae plant;
2) adopting macroporous adsorptive resins to above-mentioned steps 1) mixed extract that obtains adsorbs, wash the dehydration solubility impurity earlier with water, and then, collect eluent with ethanol aqueous wash deresination post, obtain containing the mixing eluent of Radix Ginseng total saponins and salvianolic acid;
3) to above-mentioned steps 2) the mixing eluent that obtains carries out drying, obtains the mixed extract of Radix Ginseng extract and Radix Salviae Miltiorrhizae extract.
10, medicine according to claim 9 is characterized in that: when preparing mixed extract in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 30-90%, is preferably 60%; Described return time is 30-120min, is preferably 45min;
When preparation mixed eluent described step 2), during the eluting resin column, alcoholic acid volumn concentration was 30-90% in the described ethanol water, is preferably 50-70%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
In the described step 3), it is 50-60 ℃ that the mixing eluent is carried out exsiccant temperature.
11, a kind of method for preparing arbitrary described medicine in the claim 2,3,4,5 and 7 may further comprise the steps:
1) with ethanol water or water Radix Ginseng is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain ginsenoside's extracting solution; With ethanol water Radix Salviae Miltiorrhizae is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain the salvianolic acid extracting solution;
2) adopting macroporous adsorptive resins to above-mentioned steps 1) ginsenoside's extracting solution of obtaining adsorbs, first water or ethanol water eluting water solubility impurity, and then with ethanol aqueous wash deresination post, the collection eluent obtains the Radix Ginseng total saponins eluent; Adopting macroporous adsorptive resins to above-mentioned steps 1) the salvianolic acid extracting solution that obtains adsorbs, and washes the dehydration solubility impurity earlier with water, and then with ethanol aqueous wash deresination post, the collection eluent obtains the salvianolic acid eluent;
3) to above-mentioned steps 2) the Radix Ginseng total saponins eluent that obtains carries out drying, obtains the Radix Ginseng extract powder; To above-mentioned steps 2) the salvianolic acid eluent that obtains carries out drying, obtains the Radix Salviae Miltiorrhizae extract powder;
4) with above-mentioned steps 3) the Radix Ginseng extract powder and the Radix Salviae Miltiorrhizae extract powder mixes that obtain, obtain arbitrary described medicine in the claim 2,3,4,5 and 7.
12, method according to claim 11 is characterized in that: when preparing ginsenoside's extracting solution in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 50-90%; Described return time is 30min-120min, is preferably 60min; When preparing the salvianolic acid extracting solution in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 10-60%, is preferably 50%; Described return time is 30min-120min, is preferably 30min;
When preparing ginsenoside's eluent described step 2), during the eluting water solubility impurity, alcoholic acid volumn concentration is less than 10% in the described ethanol water; During the eluting resin column, alcoholic acid volumn concentration is 50-90% in the described ethanol water, is preferably 60-70%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
When preparing the salvianolic acid eluent described step 2), during the eluting resin column, alcoholic acid volumn concentration is 30-90% in the described ethanol water, is preferably 40-60%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
In the described step 3), it is 50-60 ℃ that Radix Ginseng total saponins eluent and salvianolic acid eluent are carried out exsiccant temperature.
13, a kind of method for preparing arbitrary described medicine in the claim 2,3,4,5 and 9 may further comprise the steps:
1) with Radix Ginseng and Radix Salviae Miltiorrhizae according to 1: ratio of weight and number (0.08-20) mixes, with ethanol water or water the mixture of Radix Ginseng and Radix Salviae Miltiorrhizae is carried out reflux, extract,, the extracting solution that obtains is centrifugal, get supernatant, obtain containing the mixed extract of ginsenoside and salvianolic acid;
Described Radix Ginseng be root, stem, the leaf of plant Radix Ginseng and spend at least a;
Described Radix Salviae Miltiorrhizae is the root of plant Radix Salviae Miltiorrhizae;
2) adopting macroporous adsorptive resins to above-mentioned steps 1) mixed extract that obtains adsorbs, wash the dehydration solubility impurity earlier with water, and then, collect eluent with ethanol aqueous wash deresination post, obtain containing the mixing eluent of Radix Ginseng total saponins and salvianolic acid;
3) to above-mentioned steps 2) the mixing eluent that obtains carries out drying, obtains the mixed extract powder of Radix Ginseng and Radix Salviae Miltiorrhizae, is arbitrary described medicine in the claim 2,3,4,5 and 9.
14, method according to claim 13 is characterized in that: when preparing mixed extract in the described step 1), in the described ethanol water, alcoholic acid volumn concentration is 30-90%, is preferably 50-70%; Described return time is 30-120min, is preferably 45min;
When preparation mixed eluent described step 2), during the eluting resin column, alcoholic acid volumn concentration was 30-90% in the described ethanol water, is preferably 50-70%; Resin extender in the described macroporous adsorptive resins is a following A) or B):
A) any one in following three kinds of resins: HPD100 type resin, HPD700 type resin and S-8 type resin;
B) by in these four kinds of resins of HPD100 type, HPD700 type, S-8 type and AB-8 type any one with SephadexLH-20 gel, C18 bonding mutually with the C8 bonding at least a composite resin of forming in these three kinds mutually;
In the described step 3), it is 50-60 ℃ that the mixing eluent is carried out exsiccant temperature.
CN2008102234408A 2008-09-27 2008-09-27 Medication and preparation method and application thereof Active CN101683387B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008102234408A CN101683387B (en) 2008-09-27 2008-09-27 Medication and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2008102234408A CN101683387B (en) 2008-09-27 2008-09-27 Medication and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN101683387A true CN101683387A (en) 2010-03-31
CN101683387B CN101683387B (en) 2012-07-11

Family

ID=42046917

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008102234408A Active CN101683387B (en) 2008-09-27 2008-09-27 Medication and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN101683387B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033727A1 (en) * 2014-09-01 2016-03-10 广州市香雪制药股份有限公司 Medicine for preventing and treating vascular diseases and preparation method thereof
CN106215171A (en) * 2016-09-30 2016-12-14 广州赛莱拉干细胞科技股份有限公司 A kind of mesenchymal stem cell injection and its preparation method and application
CN106616595A (en) * 2016-11-16 2017-05-10 新乡医学院 Health-care food preparation having strong oxidation resistance and oxygen deficient resistance and application
CN106727933A (en) * 2016-12-29 2017-05-31 广州市香雪制药股份有限公司 A kind of medicine of prevention and treatment of coronary heart disease and preparation method and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1602939A (en) * 2004-08-13 2005-04-06 张正生 Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and preparing process thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033727A1 (en) * 2014-09-01 2016-03-10 广州市香雪制药股份有限公司 Medicine for preventing and treating vascular diseases and preparation method thereof
CN106215171A (en) * 2016-09-30 2016-12-14 广州赛莱拉干细胞科技股份有限公司 A kind of mesenchymal stem cell injection and its preparation method and application
CN106616595A (en) * 2016-11-16 2017-05-10 新乡医学院 Health-care food preparation having strong oxidation resistance and oxygen deficient resistance and application
CN106727933A (en) * 2016-12-29 2017-05-31 广州市香雪制药股份有限公司 A kind of medicine of prevention and treatment of coronary heart disease and preparation method and application

Also Published As

Publication number Publication date
CN101683387B (en) 2012-07-11

Similar Documents

Publication Publication Date Title
CN102600219B (en) Total flavone extract of abelmoschus manihot and preparing method of total flavone extract
CN104826087A (en) Composite moringa polypeptide and preparation method and application thereof
CN110051726A (en) The preparation method and application of general flavone and total starches in a kind of Qingqian Willow leaf
CN102293868B (en) Application of total flavonoids of lilac daphne root in preparation of medicament for reducing blood sugar
CN101181351A (en) Chinese medicine composition for resisting tiredness and reinforcing immune as well as method of making the same
CN101683387B (en) Medication and preparation method and application thereof
CN101856450A (en) Chinese medicinal composition for treating diabetic nephropathy
CN101084952B (en) Method for preparing extraction of acanthopanax senticousus saponins
CN102784182A (en) Preparation method of Radix Ginseng Rubra polysaccharide extract product
CN103349671A (en) Resveratrol and spirulina composition and preparations and preparation method thereof
CN101244208B (en) Method of preparing traditional Chinese medicine preparation for treating melancholia and anxiety neurosis
CN102357226A (en) Application of Chinese herbal medicine turmeric extraction in preparation of slimming and lipid-lowering drug or drug with lipase activity inhibition effect
CN101084955B (en) Method for preparing total ginsenoside
CN101085802B (en) Method for preparing Notoginsen triterpenes
CN1557382A (en) Glucoside compound preparation and its preparing process
CN101040896B (en) Flavone of astragalus extract, the medicine use and the compound thereof
CN102579530A (en) Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament
CN1927324A (en) Preparation method of traditional medicine preparation for treating women's menoxenia
CN102366428A (en) Applications of extracts from Chinese herbal medicine Oroxylum indicum in preparation of slimming and lipid lowering medicine or preparation of medicine with inhibition effect on activity of lipase
CN106265717B (en) Application of the dicliptera chinensis polysaccharide in preparing prevention diabetes medicament or health products
CN105055851B (en) A kind of Chinese medicine composition that treating diabetes, its preparation and its application
CN106928376A (en) The separation method of skunk bush polysaccharide and its application
CN101797365B (en) Preparation technology of Kaixiong Shunqi Jiaonang
CN102370763A (en) Application of Chinese medicinal herb immature bitter orange extract to preparation of weight-reducing and lipid-lowering medicament or preparation of medicament having lipase activity suppressing effect
CN102370708A (en) Application of extracts of Chinese herbal medicine mulberry leaf in preparation of weight-losing and lipid-lowering medicines or medicines with function of inhibiting lipase activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant